TITLE:
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer

CONDITION:
Colorectal Cancer

INTERVENTION:
Irinotecan

SUMMARY:

      This study will assess the efficacy and safety of continuous oral Xeloda administration in
      combination with intravenous irinotecan as a first-line treatment in patients with advanced
      and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months
      and the target sample size is <100 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  locally advanced and/or metastatic colorectal cancer;

          -  >=1 target lesion.

        Exclusion Criteria:

          -  previous treatment with Xeloda or irinotecan;

          -  previous systemic therapy for metastatic disease;

          -  progressive disease during previous adjuvant therapy or within 6 months of
             completion.
      
